Drug Information

Drug (ID: DG02035) and It's Reported Resistant Information

• Name: Resveratrol
• Synonyms: Resveratrol; Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4′,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
• Indication:
  In total 1 Indication(s)
  Systemic sclerosis [ICD-11: 4A42]; Phase 3
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Kidney cancer [ICD-11: 2C90]; [1]
• Target: NAD-dependent deacetylase sirtuin-1 (SIRT1); SIR1_HUMAN
• Formula: C14H12O3
• IsoSMILES: C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O
• InChI: InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
• InChIKey: LUKBXSAWLPMMSZ-OWOJBTEDSA-N
• PubChem CID: 445154
• ChEBI ID: CHEBI:45713
• TTD Drug ID: D0U3EP
• VARIDT ID: DR00287
• INTEDE ID: DR1406

Type(s) of Resistant Mechanism of This Drug

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Kidney cancer [ICD-11: 2C90]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Sirtuin 3 (SIRT3) [1]

• Metabolic Type: Mitochondrial metabolism
• Resistant Disease: Clear cell renal cell carcinoma [ICD-11: 2C90.Y]
• Molecule Alteration: Expression; Down-regulation

Differential expression of the molecule in resistant disease

• Classification of Disease: Kidney cancer [ICD-11: 2C90]
• The Specified Disease: Clear cell renal cell carcinoma
• The Studied Tissue: Kidney
• The Expression Level of Disease Section Compare with the Healthy Individual Tissue: p-value: 7.47E-39; Fold-change: -9.88E-01; Z-score: -1.66E+01
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: 786-O cells; Kidney; Homo sapiens (Human); CVCL_1051
• In Vitro Model: Caki-1 cells; Kidney; Homo sapiens (Human); CVCL_0234
• In Vitro Model: Hk-2 cells; Kidney; Homo sapiens (Human); CVCL_0302
• In Vitro Model: RPTEC cells; Kidney; Homo sapiens (Human); N.A.
• In Vitro Model: SIRT3-overexpressing 786-O cells; Kidney; Homo sapiens (Human); CVCL_1051
• In Vitro Model: SIRT3-overexpressing Caki-1 cells; Kidney; Homo sapiens (Human); CVCL_0234
• Experiment for Molecule Alteration: qRT-PCR and western blotting
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: The expression of SIRT3 improves mitochondrial function and biogenesis. Furthermore, the anti-proliferative effects of SIRT3 and RSV are increased in ccRCC through metabolic reprogramming.

References

• Ref 1: Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma. PLoS One. 2022 Jun 7;17(6):e0269432.